Regulatory Issues & Psilocybin: Compass Pathways Ltd. - Ekaterina Malievskaia | 18th February 2019

The symposium titled ’Making Psilocybin into a Medicine: A Multidisciplinary Approach’ took place on the 18th of February 2019 at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London. Ekaterina Malievskaia is Chief Innovation Officer and Co-founder of COMPASS Pathways Ltd. COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Their first programme is researching how psilocybin therapy could help people with treatment-resistant depression. Ekaterina outlines the regulatory issues COMPASS has faced in their efforts to accelerate research into and access to psilocybin. Filming & Editing: Ian Buswell